Position in ANL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$3,726,150
New position
Shares Held
538,461
first reported quarter
Ownership
0.836%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Mar 31, 2026ADAGE CAPITAL PARTNERS GP, L.L.C. holds $4,595,586,445 across 121 Biotechnology names. ANL ranks #91 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
5,475,611 | $532,503,169 | |
| 2 | RPRX |
Royalty Pharma plc
|
7,480,633 | $358,845,965 | |
| 3 | CNTA |
Centessa Pharmaceuticals plc
|
8,925,010 | $354,501,397 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
12,794,097 | $354,396,486 | |
| 5 | TNGX |
Tango Therapeutics, Inc.
|
12,809,485 | $267,974,426 | |
| 6 | PRAX |
Praxis Precision Medicines, Inc.
|
815,739 | $262,822,948 | |
| 7 | INSM |
INSMED Inc
|
900,000 | $147,168,000 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
|
737,578 | $124,665,433 |
All Filings in ANL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,726,150 | 538,461 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||